Key outcomes include reduced tumor burden and modulation of molecular markers associated with tumor stemness (SOX2), immune evasion (PD-L1, IDO), cellular proliferation (Ki67), and chemoresistance (MGMT). The gene discussed is SOX2; the disease is neoplasm.